New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
17:55 EDTMNK, QCORQuestcor's Acthar risks not included in Mallinckrodt's merger proxy, NYT says
Risks regarding the increase of adverse events related to Questcor's (QCOR) drug Acthar need to be considered by Mallinckrodt's (MNK) shareholders. Those risks were not included in last month's merger proxy, reports the New York Times. Reference Link
News For MNK;QCOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
07:25 EDTMNKTeva upgraded at Oppenheimer
Subscribe for More Information
March 27, 2015
07:57 EDTMNKMallinckrodt announces positive outcomes with H.P. Acthar gel in proteinuria
Subscribe for More Information
March 26, 2015
07:30 EDTMNKDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 23, 2015
13:23 EDTMNKLeerink pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry, discusses the strengths and weaknesses of INOmax's current patent portfolio, the likelihood Praxair's recently filed inter-partes review challenge succeeds on an Analyst/Industry conference call to be held on March 26 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use